ABBV Debt & Cash Flow
$AbbVie(ABBV)$ debt (10-Q)
Net debt ~$56 B at the end of the quarter
Net debt increased ~$9B (ImmunoGen acquisition)
$15 B new debt issued (connected to ImmunoGen and proposed Cerevel acquisitions)
$9.2 billion acquisition cost of ImmunoGen, Feb12
$15 B "issued debt in connection with the acquisition of ImmunoGen and proposed acquisition of Cerevel Therapeutics"
I had previously "guessed" it would have maturities 2027+ which is now confirmed
Details as follows:
"The total fair value of the consideration transferred to owners of ImmunoGen common stock was $9.8 billion ($9.2 billion, net of cash acquired)"
Cerevel Therapeutics Holdings acquisition expected within 2024, for ~$8.7 B
ABBV Cash Flow
Slightly worsening OCF in 1Q
49% dividend payout
https://twitter.com/DividendWave/status/1786735423395397694
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
- ZoePaul·05-06👍🏼LikeReport
- Diego Degese·05-06👍LikeReport